ImmunoPrecise
在场
ImmunoPrecise 是一家在股票代码 IPA (CA) 下上市的公司。
高管
查看带有其 11 名主要高管的组织结构图
ImmunoPrecise 搜索最多的简介
- Jennifer Bath, Chief Executive Officer and President
- Dirk Witters, Director
- Mitch Levine, Chairman of the Board
高管在ImmunoPrecise变化
- Mitch Levine已作为Chairman of the Board加入公司 (新闻发布的2023十一月28号).
- Dirk Witters已作为Director加入公司 (新闻发布的2023九月6号).
- Barry Springer已作为Director加入公司 (新闻发布的2023九月6号).
创建提醒
跟踪 ImmunoPrecise 的高管变动
生物技术
ImmunoPrecise 拥有 2,281 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
ImmunoPrecise 的最新新闻稿
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
- InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
- IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
- IPA Responds to 13D Filing
- ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
- ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
- IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
- IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
- IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
- IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
- View more press releases Close
关于 ImmunoPrecise 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Jennifer Bath 
